{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:33:52Z","timestamp":1780724032630,"version":"3.54.1"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,8,15]]},"DOI":"10.2169\/internalmedicine.4375-19","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T22:06:14Z","timestamp":1597442774000},"page":"1947-1956","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis"],"prefix":"10.2169","volume":"59","author":[{"given":"Makoto","family":"Murata","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Japan"},{"name":"Adult CML\/MPN Working Group of the Japan Society for Hematopoietic Cell Transplantation, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Shimane University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Shirane","sequence":"additional","affiliation":[{"name":"Adult CML\/MPN Working Group of the Japan Society for Hematopoietic Cell Transplantation, Japan"},{"name":"Division of Hematology, Department of Internal Medicine, Juntendo University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Shimazu","sequence":"additional","affiliation":[{"name":"Adult CML\/MPN Working Group of the Japan Society for Hematopoietic Cell Transplantation, Japan"},{"name":"Department of Hematology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[{"name":"Adult CML\/MPN Working Group of the Japan Society for Hematopoietic Cell Transplantation, Japan"},{"name":"Department of Hematology, National Cancer Center Hospital East, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanagawa Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Osaka International Cancer Institute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Togitani","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"Japanese Data Center for Hematopoietic Cell Transplantation, Japan"},{"name":"Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokiko","family":"Nagamura-Inoue","sequence":"additional","affiliation":[{"name":"Adult CML\/MPN Working Group of the Japan Society for Hematopoietic Cell Transplantation, Japan"},{"name":"Department of Cell Processing and Transfusion, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Thiele J, Kvasnicka HM, Orazi A, et al. Essential thrombocythaemia. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al., Eds. International Agency for Research on Cancer, Lyon, 2017: 50-53."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124: 2507-2513, 2014.","DOI":"10.1182\/blood-2014-05-579136"},{"key":"3","unstructured":"3. Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Birgeg\u00e5rd G, Barbui T. Polycythaemia vera. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al., Eds. International Agency for Research on Cancer, Lyon, 2017: 39-43."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798, 2012.","DOI":"10.1056\/NEJMoa1110556"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kirito K, Okamoto S, Ohishi K, et al. Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. Int J Hematol 107: 92-97, 2018.","DOI":"10.1007\/s12185-017-2332-z"},{"key":"6","unstructured":"6. Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol 91: 50-58, 2016."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Spivak JL. Myeloproliferative neoplasms. N Engl J Med 376: 2168-2181, 2017.","DOI":"10.1056\/NEJMra1406186"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 13: 355-365, 2007.","DOI":"10.1016\/j.bbmt.2006.11.004"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ballen KK, Woolfrey AE, Zhu X, et al. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant 18: 1446-1454, 2012.","DOI":"10.1016\/j.bbmt.2012.03.009"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Lussana F, Rambaldi A, Finazzi MC, et al. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 99: 916-921, 2014.","DOI":"10.3324\/haematol.2013.094284"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Atsuta Y, Suzuki R, Yoshimi A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 86: 269-274, 2007.","DOI":"10.1007\/BF03006932"},{"key":"12","unstructured":"12. Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103: 3-10, 2016."},{"key":"13","unstructured":"13. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 15: 367-369, 2009."},{"key":"14","unstructured":"14. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15: 825-828, 1995."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69: 204-217, 1980.","DOI":"10.1016\/0002-9343(80)90398-8"},{"key":"16","unstructured":"16. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18: 695-706, 1999."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cox DR. Regression models and life tables. J Royal Stat Soc [B] 34: 187-220, 1972.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Robin M, Giannotti F, Deconinck E, et al. Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant 20: 1841-1846, 2014.","DOI":"10.1016\/j.bbmt.2014.06.011"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Takagi S, Ota Y, Uchida N, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood 116: 649-652, 2010.","DOI":"10.1182\/blood-2009-11-252601"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Murata M, Takenaka K, Uchida N, et al. Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups. Biol Blood Marrow Transplant 25: 1536-1543, 2019.","DOI":"10.1016\/j.bbmt.2019.02.019"},{"key":"22","unstructured":"22. Bacigalupo A, Soraru M, Dominietto A, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 45: 458-463, 2010."},{"key":"23","unstructured":"23. Murata M, Nishida T, Taniguchi S, et al. Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT. Bone Marrow Transplant 49: 355-360, 2014."},{"key":"24","unstructured":"24. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29: 392-397, 2011."},{"key":"25","unstructured":"25. Takenaka K, Shimoda K, Uchida N, et al. Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. Int J Hematol 105: 59-69, 2017."},{"key":"26","unstructured":"26. Samuelson Bannow BT, Salit RB, Storer BE, et al. Hematopoietic cell transplantation for myelofibrosis: The Dynamic International Prognostic Scoring System Plus risk predicts post-transplant outcomes. Biol Blood Marrow Transplant 24: 386-392, 2018."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Robin M, de Wreede LC, Wolschke C, et al. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica 104: 1782-1788, 2019.","DOI":"10.3324\/haematol.2018.205211"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 93: 1514-1522, 2008.","DOI":"10.3324\/haematol.12828"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Shanavas M, Popat U, Michaelis LC, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors. Biol Blood Marrow Transplant 22: 432-440, 2016.","DOI":"10.1016\/j.bbmt.2015.10.005"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, et al. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol 101: 305-317, 2018.","DOI":"10.1111\/ejh.13099"},{"key":"31","unstructured":"31. Raj K, Eikema DJ, McLornan DP, et al. Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 25: 522-528, 2019."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4375-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T03:11:28Z","timestamp":1597461088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4375-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":31,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4375-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]}}}